Trilogy cells (green) hunt, home, and kill tumors (red).
This platform technology is able to deliver multiple therapeutic payloads and does not require lymphodepletion.
Tremendous progress has been made in the last decade in the fight against cancer using cell and gene therapies. For instance, CAR-T cells have shown a remarkable ability to put cancers of the blood into remission. Unfortunately there remains significant challenges to treating solid tumors, where circulating cells have trouble penetrating and reaching target cancerous tissue.
Trilogy cells offer a unique solution to this challenge. Trilogy cells are created by isolating and converting a patient’s own skin into tumor-homing and tumor-killing cells through a genetic reprogramming process. This imparts strong tumor-sensing and directional migration properties to the cells, making them able to ‘sniff out’ cancer cells. In addition to giving the cells a nose to smell cancer and the legs to move them there, Trilogy cells create and drop cancer killing agents once they’ve reached cancer cells. These ‘seek and destroy’ properties make Trilogy cells an exciting new approach to treating the most difficult cancers.
Sourced from the patient’s own skin, Falcon’s proprietary Trilogy cells hunt down, home to, and kill cancer. Trilogy cells are genetically modified to detect cancer cells, actively move through blood and tissue to hunt them down, and deliver targeted payloads that destroy the tumor.
An estimated 14,070 deaths were attributed to ovarian cancer in 2018, making it the deadliest gynecologic malignancy. Treatment of ovarian cancer typically includes debulking surgery and often adjuvant and/or neo-adjuvant platinum or taxane-based chemotherapy. While an initial disease-free interval is achieved in many patients, recurrence is very common in ovarian cancer, and eventual resistance to standard therapy frequently occurs. The treatment options for patients with platinum-resistant recurrent ovarian cancer or patients who do not tolerate platinum-based chemotherapy are limited.
One of the challenges in treating patients with recurrent or residual cancers, such as platinum-resistant ovarian cancer, is the ability to deliver effective treatment in a safe and efficient manner. IV delivery of Trilogy cells has the potential to treat advanced epithelial ovarian, fallopian tube or primary peritoneal cancer by delivering anti-cancer therapeutics at a quantity and persistence necessary to induce robust tumor kill.
Perhaps the most exciting aspect of Trilogy cells is that they don’t just sense a single type of cancer. We have a robust data package supporting efficacy in 12 cancer types. The current indications in Falcon’s product pipeline that are under active development are shown below.